Back to the Corporate Site
Corporate Logo

Committee Charting

Email page
PDF view Print view Email Alert
  • careers
  • site map
  • About Us
    • Overview
    • Senior Management Team
    • Board of Directors
  • Product Portfolio
    • Marketed Products
    • Product Pipeline
    • Publications
    • Business Development
      • Contact
  • Fortress Companies
    • Avenue Therapeutics
    • Caelum Biosciences
    • Cellvation
    • Checkpoint Therapeutics
    • Cyprium Therapeutics
    • Escala Therapeutics
    • Helocyte, Inc
    • Journey Medical
    • Mustang Bio, Inc.
  • Investors
      • Corporate Information
        • Corporate Profile
        • Senior Management
        • Board of Directors
      • Corporate Presentations
      • Press Releases
      • Events & Webcasts
      • Stock Information
      • Governance
        • Governance Documents
        • Committee Charting
      • SEC Filings
        • Documents
        • Section 16 Filings
        • Annual Meeting Materials
      • Other Information
        • Information Request
        • Email Notification
  • Contact Us

Committee Charting

    • Corporate Information
      • Corporate Profile
      • Senior Management
      • Board of Directors
    • Corporate Presentations
    • Press Releases
    • Events & Webcasts
    • Stock Information
    • Governance
      • Governance Documents
      • Committee Charting
    • SEC Filings
      • Documents
      • Section 16 Filings
      • Annual Meeting Materials
    • Other Information
      • Information Request
      • Email Notification
Contact Info


Fortress Biotech, Inc.
2 Gansevoort Street
9th Floor
New York, NY 10014
info@fortressbiotech.com

Investor Relations
Jaclyn Jaffe
ir@fortressbiotech.com
(781) 652-4500



Home » investors »  Governance  » Committee Charting

Committee Charting

Email page
PDF view Print view Email Alert

Committee Charting

  • By Committee
  • By Member
Dov Klein J. Jay Lobell Jimmie Harvey, Jr., M.D. Malcolm I. Hoenlein Charter Documents Charter Documents Charter Documents
Audit Committee CC
Audit Committee Charter
Compensation Committee CC
Compensation Committee Charter
Nominating and Corporate Governance Committee CC
Nominating and Coporate Governance Committee Charter
Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Dov Klein CC
J. Jay Lobell CC CC
Jimmie Harvey, Jr., M.D.
Malcolm I. Hoenlein

Audit Committee

Committee Members
CC Dov Klein
J. Jay Lobell
Jimmie Harvey, Jr., M.D.
Charter Documents
Audit Committee Charter

Compensation Committee

Committee Members
Dov Klein
CC J. Jay Lobell
Jimmie Harvey, Jr., M.D.
Charter Documents
Compensation Committee Charter

Nominating and Corporate Governance Committee

Committee Members
Dov Klein
CC J. Jay Lobell
Malcolm I. Hoenlein
Charter Documents
Nominating and Coporate Governance Committee Charter

Dov Klein

Dov Klein
Mr. Klein has served as a member of our board of directors since July 2015. Mr. Klein is an audit partner at RSSM CPA LLP, a certified public accountant and strategic advisor firm, which he joined in 2001. His practice focuses on audits and reviews and compilation of financial statements for clients in various industries. Mr. Klein also consults on matters in litigation and conducts financial due diligence in mergers and acquisitions as well as business planning for growing businesses. Mr. Klein has been a certified public accountant since 1978 and is a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants. Mr. Klein received his BSc in Accounting from Brooklyn College, City University of New York.
Committee Membership
CC Audit Committee
Compensation Committee
Nominating and Corporate Governance Committee

J. Jay Lobell

J. Jay Lobell
Mr. Lobell has served as a member of our board of directors since June 2006. Mr. Lobell is president of Meridian Capital Group, LLC, a commercial real estate mortgage company, which he joined as a senior officer in January 2010. Mr. Lobell also is a founder of, and since December 2009 has served as vice chairman of, Beech Street Capital, LLC, a real estate lending company. Since January 2005, Mr. Lobell has served as president and chief operating officer of PBS, a biotechnology investment and development company, which is largely dormant at this time. In that capacity, he had substantial responsibility for the assembly and oversight of companies founded and incubated by PBS, including Coronado. Mr. Lobell previously has served on the board of directors of NovaDel Pharma Inc., Innovive Pharmaceuticals, Inc. and ChemRx Corporation. Mr. Lobell was a partner in the law firm Covington & Burling LLP from October 1996 through January 2005, where he advised companies and individuals as a member of the firm’s securities litigation and white collar defense practice group. Mr. Lobell received his B.A. (summa cum laude, Phi Beta Kappa) from the City University of New York and his J.D. from Yale Law School, where he was senior editor of the Yale Law Journal.
Committee Membership
Audit Committee
CC Compensation Committee
CC Nominating and Corporate Governance Committee

Jimmie Harvey, Jr., M.D.

Jimmie Harvey, Jr., M.D.
Dr. Harvey has served as a member of our board of directors since December 2008. Dr. Harvey in 1984 founded Birmingham Hematology and Oncology Associates L.L.C., a private medical company located in Birmingham, Alabama. Dr. Harvey has experience in clinical trial execution and management and has recently been a principal investigator in two trials, one investigating a novel monoclonal antibody and the other a small molecule used to treat immunologic malignancies. Dr. Harvey holds a B.A. degree in Chemistry from Emory University and received his M.D. from Emory University School of Medicine. Dr. Harvey completed his medical oncology training at the Vincent T. Lombardi Cancer Center at Georgetown University.
Committee Membership
Audit Committee
Compensation Committee

Malcolm I. Hoenlein

Malcolm I. Hoenlein
Mr. Hoenlein has served as a member of our board of directors since February 2014. Since 1986, Mr. Hoenlein has served as Chief Executive Officer and Executive Vice Chairman of the Conference of Presidents of Major American Jewish Organizations, the coordinating body on international and national concerns for 51 national American Jewish organizations. Previously, he served as the founding Executive Director of the Jewish Community Relations Council of Greater New York. Prior to that, he was the founding Executive Director of the Greater New York Conference on Soviet Jewry. A National Defense Fellow at the Near East Center of the University of Pennsylvania, Mr. Hoenlein taught International Relations in the Political Science Department and served as a Middle East specialist at the Foreign Policy Research Institute. In addition, he served on the editorial staff of ORBIS, the Journal of International Affairs. He serves as a director of several companies, including Eco-Fusion, LabStyle Innovations Corp. (OTCBB: DRIO), and WellSense Technologies. Mr. Hoenlein has a B.A. in Political Science from Temple University and an M.A. in International Relations from the University of Pennsylvania, as well as an Hon. LL.D. from Touro College and an Hon. D.H.L. from Yeshiva University.
Committee Membership
Nominating and Corporate Governance Committee
CC= Chairperson
= Member
*To view the charter documents, click on committee name.

Copyright 2017, © S&P Global Market Intelligence  Terms of Use

TERMS AND CONDITIONS OF USE

PDF View Print View

The investor relations site ("Site") with which this document is associated is maintained by S&P Global Market Intelligence ("S&P") on behalf of the organization featured on the Site (S&P's "Client"). These Terms and Conditions of Use ("Terms of Use") set forth the terms on which you may use the Site, and the information and materials contained therein (the "Contents"). By using the Site, you agree to these Terms of Use. If you do not agree to these Terms of Use, you are not authorized to use the Site or Contents in any manner, and you should immediately discontinue any use of the Site or the Contents.

S&P and/or its Client shall have the right at any time to modify or discontinue any aspect of the Site or any part of the Contents. S&P may also modify these Terms of Use without notice. You agree to monitor these Terms of Use, and to cease all access or use of the Site if you no longer agree to abide by the Terms of Use. Your continued use of the Site shall constitute acceptance of such modification.

S&P and the Client grant to you a limited, personal license to access the Site and to access and download the Contents, but only for your own personal, family and household use. You may not use, reproduce, distribute or display any portion of the Site for any other purpose, including without limit any commercial purpose. You may use the Site and the Contents for lawful purposes only. S&P and Client reserve all rights not expressly granted, including the right to terminate your use of the Site without notice.

The Site contains copyrighted material, trademarks and service marks, and other proprietary information, including but not limited to text, software, and graphics, which materials are owned by S&P and/or its Client. S&P and Client reserve all rights in the Contents. You agree not to reproduce, distribute, sell, broadcast, publish, retransmit, disseminate, circulate or commercially exploit the Site or the Contents without the express written consent of S&P and the Client.

You agree to access the Contents and the Site manually, by request, and not automatically, through the use of a program, or other means. You agree not to take any action, alone or with others, that would interfere with the operation of the Site, to alter the Site in any way, or to impede others' access to and freedom to enjoy and use the Site as made available by S&P and S&P’s Client.

THE SITE AND THE CONTENTS ARE PROVIDED ON AN "AS IS" BASIS. S&P, ITS CLIENT, AND ANY OTHER PROVIDERS OF THE INFORMATION EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF ACCURACY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

NEITHER, S&P, THE CLIENT NOR EITHER OF THEIR AFFILIATES, SHAREHOLDERS, OFFICERS, EMPLOYEES, AGENTS OR REPRESENTATIVES SHALL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, EXEMPLARY , PUNITIVE SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATING TO THE SITE, THE USE OF OR INABILITY TO USE THE SITE, OR THE CONTENTS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN PARTICULAR, S&P WILL NOT BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY YOUR RELIANCE ON INFORMATION OBTAINED THROUGH THE SITE.

It is your responsibility to evaluate the accuracy, completeness or usefulness of any of the Contents available on the Site. Please seek the advice of professionals regarding the evaluation of any of the information on the Site.

The Site does not represent an offer or solicitation with respect to the purchase or sale of any security.

These Terms of Use are the entire agreement between the parties with respect to its subject matter, and it can be amended only via written agreement by S&P. These terms and conditions shall be governed by the law of New York, without regard to principals of conflicts or choice of laws.

© Copyright 2017 Fortress Biotech. All rights reserved. privacy policy disclaimer     Friend us on Facebook Follow us on Twitter! Download our app today!